Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03770637
Other study ID # XSGR-PBH-201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 10, 2019
Est. completion date February 26, 2020

Study information

Verified date May 2020
Source Xeris Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research center (CRC) visits, followed by the other treatment at the second CRC visit. Subjects will be randomly assigned to either Glucagon RTU or Placebo for the duration of a 12-week Outpatient Stage. A follow-up safety assessment visit will occur 14 to 28 days after a subject's last dose of study drug.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date February 26, 2020
Est. primary completion date February 26, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Male or female

2. Aged 18 to 75 years of age, inclusive

3. Symptoms of hypoglycemia that developed after bariatric surgery (Roux-en-Y gastric bypass [RYGB] only) in the absence of antidiabetic medications

4. History of bariatric surgery (RYGB only), at least 6 months prior to screening

5. Whipple's triad

1. Ability to both experience and recognize hypoglycemic awareness.

2. Documented glucose levels < 54 mg/dL when experiencing symptoms suggestive of hypoglycemia

3. Relief of hypoglycemia symptoms when the glucose is raised to normal

6. Diagnosis of post-bariatric hypoglycemia (PBH) by a physician, requiring intervention such as intake of oral carbohydrates. This diagnosis includes documentation of endogenous hyperinsulinism in the presence of low plasma glucose.

7. In subjects with medical history of diabetes, medical documentation of postoperative remission of diabetes mellitus (fasting glucose < 110 mg/dL), and HbA1c < 6% (or 42 mmol/mL) with all previous antidiabetic medication discontinued for at least 6 months before screening.

8. Body mass index (BMI) = 40 kg/m2

9. Willingness to follow all study procedures, including attending all clinic visits and self-administering blinded study drug at home for 12 weeks

10. Understands the study procedures, alternative treatment available, and risks involved with the study, and he/she voluntarily agrees to participate by giving written informed consent

11. Women of childbearing potential must have a negative urine pregnancy test and agree to use contraception and refrain from breast-feeding during the study and for at least 15 days after participating in the study.

Exclusion Criteria:

1. Documented hypoglycemia occurring in the fasting state (> 12 hours fast) within 12 months of study entry

2. Hypoglycemic unawareness as evidenced by a Gold Scale score > 4 at screening

3. Early Dumping Syndrome

4. Known insulinoma or adrenal insufficiency

5. Active treatment with any insulin/insulin secretagogues, or other diabetes medications except for acarbose and glucagon-like peptide 1 (GLP-1) analogues

6. Chronic kidney disease Stage 4 or 5 or an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m2 at screening

7. Hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase = 3 times the upper limit of normal (ULN); hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL

8. Congestive heart failure, New York Heart Association Class III or IV

9. History of myocardial infarction, unstable angina, or revascularization within 6 months prior to screening.

10. History of a cerebrovascular accident within 6 months prior to screening or with major neurological deficits

11. Seizure disorder (other than with suspected or documented hypoglycemia).

12. Active malignancy, except for basal or squamous cell skin cancers

13. Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)

14. Major surgical operation within 30 days prior to screening

15. Hematocrit = 30%

16. Bleeding disorder, treatment with warfarin, or platelet count < 50,000 /mm3

17. Active alcohol abuse or substance abuse (per investigator assessment)

18. Current chronic administration of oral or parenteral corticosteroids, however topical, intraarticular, and inhaled corticosteroids are allowed

19. Use of an investigational drug within 15 days or 5 half-lives, whichever is longer, prior to screening

20. Member of a special vulnerable populations such as pregnant women, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable

21. Any other medical condition or finding that in the opinion of the investigator or sponsor, would compromise the safety of the subject or compromise the integrity of the study data

Study Design


Intervention

Drug:
Glucagon RTU
Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
Other:
Placebo
The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).

Locations

Country Name City State
United States University of Colorado-Denver Aurora Colorado
United States Johns Hopkins Hospital Baltimore Maryland
United States Joslin Diabetes Center Boston Massachusetts
United States Duke Early Phase Clinical Research Durham North Carolina
United States Mayo Clinic- Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Xeris Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood glucose recovery: CRC Number of subjects with blood glucose > 70 mg/dL At 15 minutes following administration of study drug
Primary Blood glucose recovery: Out-patient Frequency of blood glucose > 70 mg/dL At 15 minutes following administration of study drug
Secondary Symptomatic Recovery: CRC Change from Baseline in Hypoglycemia Symptoms At 15, 30, and 60 minutes following administration of study drug
Secondary Incidence of severe hypoglycemia: CRC Number of subjects requiring external assistance to treat hypoglycemia At 0-240 minutes following administration of study drug
Secondary Incidence of severe hypoglycemia: Out-patient Frequency of external assistance to treat postprandial hypoglycemia During 12 weeks of out-patient treatment
Secondary Incidence of serious hypoglycemia: CRC Number of subjects with blood glucose < 54 mg/dL At 0-240 minutes following administration of study drug
Secondary Incidence of serious hypoglycemia: Out-patient Frequency of postprandial blood glucose < 54 mg/dL During 12 weeks of out-patient treatment
Secondary Hypoglycemia Fear Scale Change from Baseline in Hypoglycemia Fear Scale (HFS-2) Scores. The HFS-2 consists of two domains, Behavior, which has 15 questions, and Worry, which has 18 questions. Each question is assessed on a 5-point scale from 0=Never to 4=Almost Always. Lower scores indicate less fear of hypoglycemia, while higher scores indicate a greater level of fear. During 12 weeks of out-patient treatment
Secondary EuroQol Health Questionnaire (EQ-5D) Change from Baseline in EQ-5D Score. This is a health assessment questionnaire with three domains. The first two domains of pain/discomfort and anxiety/depression are scored on a 5-point scale from 1=no pain/discomfort; not anxious or depressed to 5=extreme pain or discomfort; extremely anxious or depressed. For these two domains, lower scores indicate less pain/discomfort or anxiety/depression, while higher scores indicate increasing levels of pain/discomfort or anxiety/depression. The third domain of Health is assessed with a series of 5 visual analog scales, each scored from 0-100. On these VAS scales, high scores indicate better health, while low scores indicate worse health. During 12 weeks of out-patient treatment
See also
  Status Clinical Trial Phase
Completed NCT03984370 - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass Phase 2
Recruiting NCT05597475 - GLP1R-imaging in Post-RYGB Hypoglycemia N/A
Completed NCT03103009 - Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia Phase 1
Completed NCT02685852 - Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Phase 1
Completed NCT01933490 - Post-Gastric Bypass Hypoglycemia N/A
Completed NCT04836273 - Treatment of Post-bariatric Hypoglycaemia Phase 2
Recruiting NCT03930368 - Application of Raw Corn Starch on Patients With Insulinoma N/A